Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: Steady-state pharmacokinetics

Contraception

Volumn 87, Issue 6, 2013, Pages 738-743

  Thurman, Andrea ^a   Kimble, Thomas ^a   Hall, Peter ^b   Schwartz, Jill L ^c   Archer, David F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b Concept Foundation ^*  (Thailand)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Combined contraceptive; Cyclofem; Injectable contraceptive; Lunelle; Pharmacokinetics

Indexed keywords

ESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ADULT; ANKLE EDEMA; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTRACEPTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLOW UP; GAS CHROMATOGRAPHY; HUMAN; INJECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; OVULATION; PHASE 1 CLINICAL TRIAL; PROGESTERONE BLOOD LEVEL; RASH; STEADY STATE; SUSPENSION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; BIOLOGICAL AVAILABILITY; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUGS, INVESTIGATIONAL; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDROXYPROGESTERONE ACETATE; METABOLIC CLEARANCE RATE; OVARY; OVULATION INHIBITION; SUSPENSIONS;

EID: 84877717681     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2012.11.010     Document Type: Article

References (18)

1. C. Westhoff Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety Contraception 68 2 2003 75 87
2. A.M. Kaunitz Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians Int J Fertil Womens Med 43 1998 73 83
3. C. Moreau, K. Cleland, and J. Trussell Contraceptive discontinuation attributed to method dissatisfaction in the United States Contraception 76 2007 267 272
4. B. Vaughan, J. Trussell, K. Kost, S. Singh, and R. Jones Discontinuation and resumption of contraceptive use: results from the 2002 National Survey of Family Growth Contraception 78 4 2008 271 283
5. healthy pople.gov. 2010 [cited 19 January 2010]; Available from: http://www.healthypeople.gov/document/html/objectives/09-01.htm.
6. K. Fotherby, G. Benagiano, and H.K. Toppozada A preliminary pharmacological trial of the monthly injectable contraceptive cycloprovera Contraception 25 1982 261 272
7. J. Garza-Flores, V. Rodriguez, and G. Perez-Palacios A multicentered pharmacokinetic, pharmacodynamic study of once-a-month injectable contraceptives. I. Different doses of HRP112 and of DepoProvera. World Health Organization Task Force on Long-acting Systemic Agents for Fertility Regulation Contraception 36 1987 441 457
8. P.E. Hall New once-a-month injectable contraceptives, with particular reference to Cyclofem/Cyclo-Provera Int J Gynaecol Obstet 62 Suppl. 1 1998 S43 S56
9. S. Said, W. Sadek, and A. Knoieif A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection: I. Contraceptive efficacy and side effects. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Contraception 37 1988 1 20
10. A.M. Kaunitz, R.J. Garceau, and M.A. Cromie Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group Contraception 60 1999 179 187
11. M.H. Rahimy, K.K. Ryan, and N.K. Hopkins Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): steady-state pharmacokinetics of MPA and E2 in surgically sterile women Contraception 60 1999 209 214
12. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. Update 2008. http://whqlibdoc.who.int/hq/2008/WHO-RHR-08.19-eng.pdf.
13. D.R. Mishell Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception J Reprod Med 41 5 Suppl 1996 381 390
14. M.H. Rahimy, and K.K. Ryan Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women Contraception 60 1999 189 200
15. M.H. Rahimy, M.A. Cromie, N.K. Hopkins, and D.M. Tong Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): effects of body weight and injection sites on pharmacokinetics Contraception 60 1999 201 208
16. A.R. Aedo, B.M. Landgren, E. Johannisson, and E. Diczfalusy Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations Contraception 31 1985 453 469
17. X.F. Zhou, Q.X. Shao, X.J. Han, L.J. Weng, and G.W. Sang Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of Cyclofem in Chinese women Contraception 57 1998 405 411
18. M.S. Diaz-Cruz, M.J. Lopez de Alda, R. Lopez, and D. Barcelo Determination of estrogens and progestogens by mass spectrometric techniques (GC/MS, LC/MS and LC/MS/MS) J Mass Spectrom 38 2003 917 923